Oncolys BioPharma EBIT

The latest EBIT for 4588.T is $-1.5B as of June 2026. That compares with $-2.2B in the prior-year period — up 31.0% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Oncolys BioPharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, 4588.T's EBIT moved from $-2.2B to $-1.5B — a 31.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Oncolys BioPharma's operating scale or balance-sheet position.

Against Healthcare companies, 4588.T currently prints $-1.5B for EBIT, while the sector average sits near $110B. That is roughly 101.4% below the sector mean. Large gaps often invite a closer look at Oncolys BioPharma's growth, margins, and balance sheet.

A EBIT figure of $-1.5B for 4588.T is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting 4588.T's EBIT ($-1.5B), review year-over-year change from $-2.2B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.